TuHURA Biosciences, Inc. (NASDAQ:HURA) Given Consensus Recommendation of “Buy” by Brokerages

TuHURA Biosciences, Inc. (NASDAQ:HURA) has received a consensus rating of “Buy” from the six brokerages that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, three have given a buy rating and two have given a strong buy rating to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $10.3333.

A number of equities research analysts have recently commented on HURA shares. Wall Street Zen downgraded TuHURA Biosciences from a “hold” rating to a “sell” rating in a research report on Sunday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of TuHURA Biosciences in a research note on Wednesday, October 8th. Finally, Maxim Group dropped their target price on shares of TuHURA Biosciences from $15.00 to $8.00 and set a “buy” rating on the stock in a research report on Friday, November 14th.

TuHURA Biosciences Price Performance

HURA opened at $0.96 on Tuesday. The business has a fifty day moving average price of $2.11 and a 200 day moving average price of $2.44. The stock has a market capitalization of $49.38 million, a price-to-earnings ratio of -1.93 and a beta of -0.03. TuHURA Biosciences has a 12 month low of $0.93 and a 12 month high of $5.50.

TuHURA Biosciences (NASDAQ:HURA) last posted its quarterly earnings data on Friday, November 14th. The company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.01.

Hedge Funds Weigh In On TuHURA Biosciences

Several institutional investors have recently bought and sold shares of HURA. Suncoast Equity Management raised its position in TuHURA Biosciences by 4.4% in the second quarter. Suncoast Equity Management now owns 104,409 shares of the company’s stock worth $233,000 after purchasing an additional 4,412 shares in the last quarter. Virtu Financial LLC acquired a new stake in TuHURA Biosciences during the third quarter valued at approximately $26,000. JPMorgan Chase & Co. bought a new stake in shares of TuHURA Biosciences in the 2nd quarter valued at approximately $27,000. Intech Investment Management LLC acquired a new position in shares of TuHURA Biosciences in the 2nd quarter worth approximately $29,000. Finally, Invesco Ltd. acquired a new position in shares of TuHURA Biosciences in the 2nd quarter worth approximately $30,000. 0.62% of the stock is currently owned by institutional investors.

TuHURA Biosciences Company Profile

TuHURA Biosciences, Inc (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.